Inhibition of complement component C5 protects porcine chondrocytes from xenogeneic rejection

• Published in: Osteoarthritis and cartilage Vol. 21; no. 12; pp. 1958 - 1967
• Main Authors: Sommaggio, R, Pérez-Cruz, M, Brokaw, J.L, Máñez, R, Costa, C
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2013
• Subjects: Animals; Antibodies, Monoclonal - pharmacology; Cartilage, Articular - cytology; Cartilage, Articular - drug effects; CD59 Antigens - immunology; Chemokines; Chondrocytes; Chondrocytes - transplantation; Complement; Complement C5 - antagonists & inhibitors; Complement C5 - immunology; Complement C5 - pharmacology; Complement C5a - immunology; Complement Membrane Attack Complex - immunology; Cytokines; Galactosyltransferases - genetics; Graft Rejection - prevention & control; Graft Survival - drug effects; Heterografts - immunology; Histocompatibility Antigens Class II - immunology; Humans; Interleukin-6 - immunology; Interleukin-8 - immunology; Mice; Mice, Knockout; Rheumatology; Swine; Transplantation, Heterologous - methods; Xenotransplantation; Complement; Cytokines; Xenotransplantation; Chemokines; Chondrocytes
• ISSN: 1063-4584; 1522-9653
• DOI: 10.1016/j.joca.2013.09.002

Summary Objective Tissue-based xenografts such as cartilage are rejected within weeks by humoral and cellular mechanisms that preclude its clinical application in regenerative medicine. The problem could be overcome by identifying key molecules triggering rejection and the development of genetic-engineering strategies to counteract them. Accordingly, high expression of α1,2-fucosyltransferase (HT) in xenogeneic cartilage reduces the galactose α1,3-galactose (Gal) antigen and delays rejection. Yet, the role of complement activation in this setting is unknown. Design To determine its contribution, we assessed the effect of inhibiting C5 complement component in α1,3-galactosyltransferase-knockout (Gal KO) mice transplanted with porcine cartilage and studied the effect of human complement on porcine articular chondrocytes (PAC). Results Treatment with an anti-mouse C5 blocking antibody for 5 weeks enhanced graft survival by reducing cellular rejection. Moreover, PAC were highly resistant to complement-mediated lysis and primarily responded to human complement by releasing IL-6 and IL-8. This occurred even in the absence of anti-Gal antibody and was mediated by both C5a and C5b-9. Indeed, C5a directly triggered IL-6 and IL-8 secretion and up-regulated expression of swine leukocyte antigen I (SLA-I) and adhesion molecules on chondrocytes, all processes that enhance cellular rejection. Finally, the use of anti-human C5/C5a antibodies and/or recombinant expression of human complement regulatory molecule CD59 (hCD59) conferred protection in correspondence with their specific functions. Conclusions Our study demonstrates that complement activation contributes to rejection of xenogeneic cartilage and provides valuable information for selecting approaches for complement inhibition.